Third quarter results highlight strong operational performance across key value drivers: YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris ...
GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...
In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...
We hope today is manageable and productive. Best of luck, and keep in touch. … GSK plans to depart the biotechnology industry ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
ii This approval underscores GSK's commitment to help drive progress for people living with complex blood cancers.
GlaxoSmithKline (GSK) has firmly acquired the number one position ... and he held the position of Vice-Chairman for PhRMA Local Working Group in Jordan. Discover how AI is transforming the pharma ...
GSK’s Meningococcal Group B Vaccine has been licensed in over 40 countries, including member states of the European Union, Argentina, Australia, Canada, Chile, Israel, New Zealand, Turkey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback